neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children “The availability of a needle-free epinephrine option for children is a breakthrough in the treatment ...

Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect ARS Pharmaceuticals has also submitted a supplemental New Drug Application ...

The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as ...

An education module for internal medicine residents improves counseling of patients with food allergies on the use of ...

California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools. SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Na ...

There’s no cure for allergies, but treatment can improve your quality of life ...

Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Supports neffy’s potential to be a safe and ...

SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients ...

Epinephrine is a commonly used agent for a variety of indications and clinical scenarios within the emergency department. It is commonly administered during cardiopulmonary arrest and serves as an ...

SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves ...

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...